Stay updated on Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    No substantive changes detected in the study record between the two screenshots. The page continues to display the same study title, conditions, eligibility criteria, and planned interventions.
    Difference
    0.5%
    Check dated 2025-11-03T01:30:54.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    34 days ago
    Change Detected
    Summary
    - Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.
    Difference
    4%
    Check dated 2025-10-05T10:18:41.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Updated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.
    Difference
    0.1%
    Check dated 2025-09-28T03:16:52.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.0.2, replacing v3.0.1, indicating a version update. The 'Back to Top' element was removed as a minor UI change.
    Difference
    0.3%
    Check dated 2025-09-13T17:09:44.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.3%
    Check dated 2025-09-06T14:34:17.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated to include new facility and location information, as well as additional drug information and recent publications related to HER2-positive gastric cancer. Notably, the drug information now includes details about Pembrolizumab and Cisplatin.
    Difference
    15%
    Check dated 2025-08-30T11:20:27.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Trastuzumab Combo in HER2+ Gastric Cancer Clinical Trial page.